Syngene International Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/vif804t2dfdk4v5psbyj3v2b.pdf

Key Takeaways


FY22 Performance & Division-Level Drivers

Hunt: "I am pleased with the strong finish we had to the year and that we delivered results at the high end of our upgraded guidance range."

Capacity Expansion & Infrastructure


Client & Partnership Momentum

Hunt: "Reflecting on the pandemic period, we created more than 1000 new jobs in the last two years and gained more than 100 new clients in the last year. We also extended and expanded our long-term partnership with Amgen Inc. and continued to invest in new capacity and technology to underpin future growth."

Margin & Profitability Outlook


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthMid-teens growth in revenue from operationsFY23
EBITDA marginAround 30%FY23
PAT growthSingle-digit growth, driven by 200–300 bps effective tax rate increaseFY23
Improved growth and operating leverageReturn of operating leverage after the FY23 investment step-upFY24
Amgen dedicated labBuild and operate a dedicated laboratory to accelerate small molecule scale-upBy end-2026
Mangalore regulatory approvalAchieve a major regulatory approval to broaden project scopeNo date (on track)
Hyderabad further expansionAdditional expansion beyond the completed Phase threeYear ahead (FY23)
Remdesivir manufacturingContinue manufacturing under voluntary Gilead licenceAs long as pandemic persists

Key Metrics

MetricQ4 FY22
Revenue from operations₹758 Cr, +15% YoY and +18% QoQ
Total revenue₹773 Cr, +14% YoY and +18% QoQ
EBITDA₹265 Cr, +13% YoY and +23% QoQ
EBITDA margin34%, vs 35% in Q4 FY21
PAT (before exceptional items)₹148 Cr, +7% YoY and +42% QoQ
PAT margin (before exceptional items)19%, vs 20% in Q4 FY21
EPS (basic)₹3.71, vs ₹4.04 in Q4 FY21 and ₹2.57 in Q3 FY22
FY23 revenue growth guidanceMid-teens, from operations
FY23 EBITDA margin guidanceAround 30%
FY23 effective tax rate increase guidance200–300 bps increase expected
FY23 PAT growth guidanceSingle digit for the full year
Dividend per share (regular + special)₹1.00 (50 paisa regular + 50 paisa special), recommended
New clients added (last year)More than 100
IDD project growth (FY22 vs FY21)~40% increase in number of projects
Scientists at Hyderabad facility~600 after phase three completion